SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 19, 2020
BIOHITECH GLOBAL, INC.
(Exact Name of Registrant as
Specified in its Charter)
|(State of Organization)
||(Commission File Number)
80 Red Schoolhouse Road, Suite 101,
Chestnut Ridge, NY 10977
(Address of principal executive offices)
Registrant’s telephone number, including
area code: 845-262-1081
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|¨||Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section
12(b) of the Act:
|Title of each class
|Name of each exchange on which registered|
$0.0001 par value per share
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 19, 2020, the Registrant issued
a press release announcing its results for the three months ended September 30, 2020. A copy of the press release is attached as
Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The information in this Form 8-K, including
the accompanying exhibit, is being furnished under Item 2.02 and shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly
set forth by specific reference in such filing.
We do not have, and expressly disclaim,
any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances
on which any forward-looking statement is based.
Item 9.01. Financial Statements and
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|Date: November 20, 2020
||BIOHITECH GLOBAL, INC.|
||/s/ Brian C. Essman|
||Brian C. Essman|
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)